n Cardiovascular Journal of South Africa - CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand(R)) : drug trends in cardiology




Extracted from text ... 252 Further analysis of the CHARM study focusing on patients with chronic heart failure (CHF) and impaired LV function in the CHARM-Alternative trial (patients received candesartan instead of an ACE inhibitor) and CHARMAdded (patients receiving candesartan plus ACE inhibitor) has shown a significant reduction in deaths and CHF hospital admissions in patients receiving this angiotensin-receptor blocker. The overall CHARM programme, announced at the European Society Congress (ESC) last year, had included a third, CHARM-Preserved trial, which investigated CHF patients with uncompromised left ventricular ejection fraction (LVEF above 40%). The pre-specified analysis of the 4 576 CHARM patients with heart failure ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error